CapsoVision (CV) Operating Margin (2024 - 2025)

CapsoVision (CV) reported Operating Margin of 190.51% for Q4 2025, down 5626.0% on a YoY basis from 3.45% in Q4 2024, and up 15.95% sequentially from 226.65% in Q3 2025.

CapsoVision (CV) Operating Margin (2024 - 2025) Analysis & Trends

CapsoVision (CV) has 2 years of Operating Margin data on file, last reported at 190.51% in Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin fell 5626.0% year-over-year to 190.51%; the trailing twelve-month figure through Dec 2025 stood at 174.14% (changed N/A YoY), and the FY2025 full-year result was 188.25%, down 1883.0% from the prior year.
  • Operating Margin improved to 190.51% in Q4 2025, from 226.65% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 134.24% in Q4 2024 to a low of 226.65% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 12.05%
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 15.55%
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 19.10%
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 21.16%
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 28.97%
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 21.42%
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 6.17%
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 10.04%
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 CapsoVision 162.07 Mn 151.95 Mn 1.95 Mn -190.51%

Historic Data

Download Data
DateValue
Dec 31, 2025 -190.51%
Sep 30, 2025 -226.65%
Jun 30, 2025 -140.30%
Dec 31, 2024 -134.24%
Sep 30, 2024 -195.65%
Jun 30, 2024 -185.40%